Dediabetes Logo
Questions
Published answers connected to evidence
Clinical Reference
Detailed intervention and outcome dossiers
Latest Research
Newest studies
About
How deDiabetes works
Settings
Login / Sign-up
Research Summary
Analyzed using Evidence Intelligence™

Atorvastatin may slow beta cell decline in type 1 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Last updated September 10, 2026

Key finding

The subgroup defined by high baseline CRP concentrations exhibited higher stimulated C-peptide secretion after statin treatment (p = 0.044).

This study investigated the effects of atorvastatin on beta cell function in type 1 diabetes, finding that atorvastatin may enhance stimulated C-peptide secretion in certain subgroups.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study investigated the effects of atorvastatin on beta cell function in type 1 diabetes, finding that atorvastatin may enhance stimulated C-peptide secretion in certain subgroups.

Clinical relevance

Preserving beta cell function is crucial in managing type 1 diabetes, as it directly impacts insulin production and overall metabolic control. If atorvastatin can effectively slow this decline, it could represent a significant advancement in diabetes care, potentially improving long-term outcomes for patients.

Keep in mind

The study's sample size may limit the generalizability of the findings. Subgroup analyses may not have sufficient power to detect differences. The trial duration may not be long enough to assess long-term effects.

Published in

Journal Reference

Publication details and source links for this paper.

Alexander S, Hubert K, Stephan M, et al. Atorvastatin treatment may slow decline of beta cell function in type 1 diabetes. PLoS ONE. 2012;7(3):e33108. doi:10.1371/journal.pone.0033108

View DOI

Main Effects

Atorvastatin treatment resulted in a significant increase in stimulated serum C-peptide in participants with high baseline CRP (p = 0.044).

No significant differences in C-peptide outcomes were observed across subgroups defined by age, sex, or baseline metabolic parameters.

A significant correlation was found between baseline CRP levels and C-peptide outcomes in the atorvastatin group (r² = 0.3079, p<0.004).

No significant correlation was observed in the placebo group.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Atorvastatin and C-peptide, Correlation of baseline CRP levels with C-peptide outcome.

This study contributes evidence to

Intervention

Atorvastatin

Outcome

C-peptide

Evidence topic

C-Peptide

Primary intervention

Atorvastatin

Primary outcomes

  • C-peptide
  • Correlation of baseline CRP levels with C-peptide outcome

Evidence topics

C-Peptide

Primary intervention

Atorvastatin

Primary outcomes

C-peptideCorrelation of baseline CRP levels with C-peptide outcome

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

2
Evidence pairs
2
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 51

1

Related topics

2

Evidence pairs

27

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 2 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence topic

C-Peptide

matched_outcome

Core evidence

Study findings

The primary outcomes reported in this study.

C-peptide

Atorvastatin → C-peptide

Atorvastatin → C-peptide

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Correlation of baseline CRP levels with C-peptide outcome

Atorvastatin → Correlation of baseline CRP levels with C-peptide outcome

Atorvastatin → Correlation of baseline CRP levels with C-peptide outcome

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • Atorvastatin increased stimulated C-peptide by 0.1 nmol/L in high CRP subgroup (p = 0.044).
  • No change in C-peptide was observed in the placebo group.
  • Correlation of baseline CRP with C-peptide outcome was significant in the atorvastatin group (r² = 0.3079, p<0.004).
who this applies

Who this applies to

  • Individuals diagnosed with type 1 diabetes.
  • Patients with elevated baseline CRP levels.
keep in mind

Keep in Mind

  • Results may not apply to individuals without elevated CRP levels.
  • The findings are based on a specific population and may not reflect broader diabetes populations.
  • Further research is needed to confirm long-term effects and benefits of atorvastatin in this context.
between the lines

Between the Lines

  • The study's sample size may limit the generalizability of the findings.
  • Subgroup analyses may not have sufficient power to detect differences.
  • The trial duration may not be long enough to assess long-term effects.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Atorvastatin and C-peptide Levels, Atorvastatin and Correlation of baseline CRP levels with C-peptide outcome.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Atorvastatin improve c-peptide?

Emerging Evidence

Atorvastatin appears to improve c-peptide.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    C-peptide

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Atorvastatin improve correlation of baseline crp levels with c-peptide outcome?

Emerging Evidence

Atorvastatin appears to improve correlation of baseline crp levels with c-peptide outcome.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Correlation of baseline CRP levels with C-peptide outcome

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

C-Peptide Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Atorvastatin and C-peptideAll studies on Atorvastatin and Correlation of baseline CRP levels with C-peptide outcome

Related research

Read related research summaries.

High-protein diet shows little effect on glycemic control in diabetesQCC Model Enhances Diabetes ManagementSaxagliptin may maintain beta-cell function in type 1 diabetesA. hookeri extract may improve glycemic control in prediabetesCarbohydrate restriction lowers HbA1c but not β-cell function in T2D

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.